Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia

por Cornely, Oliver A, Ostermann, Helmut, Koehler, Philipp, Teschner, Daniel, Limburg, Endrik, Kramer, William G, Barbat, Sara H, Tawadrous, Margaret, Hodges, Michael R
Publicado 2023

1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candi...

por Bulpa, Pierre, Rahav, Galia, Oren, Ilana, Aoun, Mickaël, Thompson, George R, Pappas, Peter, Kullberg, Bart Jan, Vazquez, Jose A, Barbat, Sara, Wedel, Pamela, Schlamm, Haran T, Hodges, Michael
Publicado 2020

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

por Pappas, Peter, Kullberg, Bart Jan, Vazquez, Jose A, Oren, Ilana, Rahav, Galia, Aoun, Mickaël, Bulpa, Pierre, Ben-Ami, Ronen, Ferrer, Ricard, McCarty, Todd P, Thompson III, George R, Barbat, Sara, Wedel, Pamela, Oborska, Iwonka, Schlamm, Haran T, Hodges, Michael
Publicado 2020

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

por Pappas, Peter G, Vazquez, Jose A, Oren, Ilana, Rahav, Galia, Aoun, Mickael, Bulpa, Pierre, Ben-Ami, Ronen, Ferrer, Ricard, Mccarty, Todd, Thompson, George R, Schlamm, Haran, Bien, Paul A, Barbat, Sara H, Wedel, Pamela, Oborska, Iwona, Tawadrous, Margaret, Hodges, Michael R
Publicado 2023